Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland

Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE): Evaluation of a Prediction Rule

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01277536

Enrollment

1478

Registered

2011-01-17

Start date

2010-12-31

Completion date

2011-11-30

Last updated

2014-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Brief summary

Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated. The goal of this project is to indirectly validate a model developed in Geneva by a non -interventional study involving the collection of patient characteristics during the hospitalization and a 3-month follow-up. These data will allow for the determination of the patient's risk, according to the Geneva model, and its validity, according the actual thrombo-embolic events, corrected for the thromboprophylaxis received. The project is multicentric in Switzerland (5-10 centers) and should involve about 1000 patients. First amendment (may 2011) : we have obtained the IRB approval for collecting data from patients who die during their hospital stay and for whom informed consent is not be possible to obtain.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients admitted (minimal stay \>24 hours) to medical hospital wards * Age ≥18 years * Ability to give an informed consent, as informed by the physicians in charge of the patient

Exclusion criteria

* Patients admitted to non-medical hospital wards * Patients with therapeutic anticoagulation at hospital admission * Patients admitted for a disease requiring therapeutic anticoagulation (MTE or other) * Patients unable to give an informed consent, as informed by the physicians in charge of the patient * Patients without signed informed consent * Patients already included in this study

Design outcomes

Primary

Measure	Time frame	Description
relationship between the combined rate of fatal and non-fatal symptomatic venous thromboembolism and bleeding events and the calculated risk score at 90 days after hospital admission	90 days	evaluation of the relationship between the combined rate of fatal and non-fatal symptomatic venous thromboembolism and bleeding events at 90 days after hospital admission on one hand, and the calculated risk score provided by the Geneva Risk Assessment Models (RAM) at hospital admission on the other hand

Countries

Switzerland

Outcome results